Original Research

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry

Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C

International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:3193-3199

Published Date: 3 December 2020